Bioretec Ltd Company Announcement 5 May 2022 at 9.00 a.m. EEST
Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted a De Novo request for market authorization in the United States for the RemeOs™ trauma screw based on bioresorbable magnesium alloy. Bioretec estimates the market authorization in the United States to be granted during the second half of 2022. The previously communicated estimate was in the first half of 2022.
The De Novo request provides a registration pathway for novel medical devices for which there is no predicate device available in the U.S. market. In spring 2021, the U.S. Food and Drug Administration (FDA) granted the RemeOs™ trauma screw a Breakthrough Device Designation status, demonstrating that the product represents breakthrough technology and offers significant advantages over existing approved products. The submission of the De Novo market authorization application has been preceded by interactive discussions under the FDA's Breakthrough Device program.
"Filing for market authorization for our new product in the United States is a strategic step for us, as the United States is the world's largest individual market for orthopedic trauma products. Our goal is to be the first to commercialize bioresorbable metal implants in the U.S. market. I believe there is demand in this growth market for our products that contribute to patient healing, safety, and cost-efficiency in clinical care. Our bioresorbable implants offer the healthcare system the opportunity to treat bone fractures more effectively by reducing the number of surgeries, and our innovative products have the potential to significantly improve the quality of life for patients. I would like to thank our team for their hard work in reaching this milestone," says Timo Lehtonen , CEO of Bioretec.
Certified Adviser: Nordic Certified Adviser AB, tel. +46 70 551 67 29
Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOs™ product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities. Better Healing - Better Life. www.bioretec.com.
This information was brought to you by Cision http://news.cision.com
With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.
‘Tell me you live in America without telling me that you live in America’
Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. No dose-limiting toxicities were observed within three months of DSG3-CAART infusion through cohort A4 (2.5 billion cells). There was a dose-dependent increase in DSG3-CAART persistence through day 29 in cohorts A1 to A4, indicating that DSG3-CAART cells were not eliminated throu
Dr. Yashica Robinson, Board member of Physicians for Reproductive Health and the director of the Alabama Women’s Wellness Center testified today in front of the House Judiciary Committee hearing to examine abortion access and care across the country. Robinson is the head of one of the last few abortion clinics in her state. While speaking before the committee Robinson emphasized the importance of abortion as essential health care.
Companies that collect data from the digital clues people leave online often know their most sensitive health information _ gleaned from web searches, health apps and location trackers
To new parents, many things are terrifying—yet few of them are as scary as Sudden Infant Death Syndrome, or SIDS. Much of how and why SIDS occurs is still unknown, but a new piece of research, published last week in eBioMedicine, found clues suggesting that there might be a biological component to it. Compared to other babies, both living and who died of other causes, infants who died of SIDS were consistently found to have lower levels of butyrylcholinesterase, an enzyme that helps provide arousal from sleep.
Eileen Wassermann struggles to calculate her daily risks at this stage of the coronavirus pandemic - with infections drastically undercounted and mask mandates gone. The immunocompromised 69-year-old ensconces herself in her SUV for the half-hour ferry ride across the Puget Sound from her home on Bainbridge Island to Seattle, where she undergoes treatment for the rare inflammatory condition sarcoidosis.Subscribe to The Post Most newsletter for the most important and interesting stories from The
A rehabilitation services provider describes the cycle that keeps people homeless, incarcerated and untreated for their mental illness.
Rebel Wilson declared 2020 her "year of health." Now, she's lost 77 pounds, thanks to a combination of walking and a high-protein diet. Here's how she did it:
The stock market continues to be under pressure due to geopolitical tensions and various economic problems. For instance, cancer-focused biotech company Exelixis (NASDAQ: EXEL) has run circles around the broader market year to date. Can Exelixis continue beating the market from here on out?
Monkeypox is a viral infection that shares similarities with smallpox
WASHINGTON (AP) — At the center of the nationwide baby formula shortage is a single factory: Abbott Nutrition’s plant that […] The post EXPLAINER: What we know about shuttered baby formula plant appeared first on TheGrio.
In the immediate aftermath of a high-profile suicide of a beloved celebrity like Naomi Judd, calls to suicide-prevention hotlines tend to increase.
COVID-19 cases are increasing in the United States – and could get even worse over the coming months, federal health officials warned Wednesday in urging areas hardest hit to consider reissuing calls for indoor masking.
A handful of cases of monkeypox have now been reported or are suspected in the United Kingdom, Portugal and Spain. The outbreaks are raising alarm because the disease mostly occurs in west and central Africa, and only very occasionally spreads elsewhere. Monkeypox is a virus that causes fever symptoms as well as a distinctive bumpy rash.
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride
Speaker Nancy Pelosi (D-Calif.) Tuesday suggested there could be indictments for the people found to be responsible for the deaths of two infants who consumed baby formula that may have been contaminated. Speaking at a press conference to unveil Democrats’ $28 million aid bill to help put formula back on store shelves, Pelosi said the…
Cases have recently been reported in Britain, Portugal, and Spain, according to the AP and Stat News.
Findings point to importance of cannabis-specific prevention and treatment efforts, scientists say
COVID-19 is evolving faster than ever before. Experts warn that the time has come to rethink our reliance on the vaccine status quo and double down on next-generation vaccines that can actually stop infection.